JAK2V617F Mutation in Patients with Splanchnic Vein Thrombosis
- 19 August 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Digestive Diseases and Sciences
- Vol. 55 (6), 1770-1777
- https://doi.org/10.1007/s10620-009-0933-y
Abstract
Splanchnic vein thrombosis can be the presenting manifestation of myeloproliferative neoplasms. However, the diagnosis of a myeloproliferative neoplasm in these patients is often problematic, and more objective criteria are needed. To determine the frequency of the mutation JAK2V617F in patients with splanchnic vein thromboses. A consecutive series of 108 adult patients with portal vein thrombosis (n = 77) and Budd-Chiari syndrome (n = 31) referred for hemostasis evaluation was retrospectively studied, with a median follow-up of 51 months (1–104). One or more prothrombotic risk factors were present in 63% of the patients. Twenty-four (22%) out of the 108 patients presented the JAK2V617F, including 2 cirrhotic patients. Most had a low mutated allele burden (median 16.5%). JAK2V617F was present in all four patients with a previous diagnosis of a myeloproliferative neoplasm. In nine JAK2V617F-positive patients, the diagnosis of a myeloproliferative neoplasm was made at the thrombosis work-up, during follow-up or after JAK2V617F detection. Among the other 11 patients carrying the mutation, 2 patients have died, 4 had no evidence suggesting a myeloproliferative neoplasm, 1 had a normal bone marrow biopsy, and the other 4 could not be persuaded to undergo a biopsy. Among the patients without an overt myeloproliferative neoplasm, 15 out of 99 (15%) presented the JAK2V617F mutation. None of the JAK2V617F-negative patients have developed signs of a myeloproliferative neoplasm during follow-up. Our findings suggest that JAK2V617F occurs in a high proportion of patients with splanchnic vein thrombosis, and reinforces the diagnostic utility of JAK2V617F testing in this setting.Keywords
This publication has 44 references indexed in Scilit:
- JAK2V617F Mutation Screening as Part of the Hypercoagulable Work-up in the Absence of Splanchnic Venous Thrombosis or Overt Myeloproliferative Neoplasm: Assessment of Value in a Series of 664 Consecutive PatientsMayo Clinic Proceedings, 2008
- JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosisBlood, 2007
- Prevalence of the Activating JAK2 Tyrosine Kinase Mutation V617F in the Budd–Chiari SyndromeGastroenterology, 2006
- Elevated serum erythropoietin levels in patients with Budd‐Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysisEuropean Journal of Haematology, 2006
- Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disordersBlood, 2005
- Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosisBritish Journal of Haematology, 2005
- Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisCancer Cell, 2005
- Polycythemia vera: myths, mechanisms, and managementBlood, 2002
- Venous thrombosis: a multicausal diseaseThe Lancet, 1999
- Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)Nucleic Acids Research, 1989